Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE-TB: 4-month Rifapentine-based Regimen for Pulmonary Tuberculosis
NCT04856644Phase 3Active, not recruiting
- Sponsor
- Kaohsiung Veterans General Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rifapentine, moxifloxacin in Tuberculosis (TB), sponsored by Kaohsiung Veterans General Hospital. Started Jan 2020; status: active, not recruiting.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04856644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856644.